Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VASCEND: Valsartan/Sacubitril vs Valsartan in HFrEF
NCT03168568Phase 4Completed
- Sponsor
- University of Zurich
- Start
- May 2017
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of sacubitril + valsartan in heart failure with reduced ejection fraction (HFrEF), sponsored by University of Zurich. Primary endpoint: Flow-mediated vasodilatation at 3 months. Started May 2017; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT03168568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03168568.